Kaufman Rossin Wealth LLC Takes $282,000 Position in Natera, Inc. $NTRA

Key Points

• Kaufman Rossin Wealth LLC invested approximately $282,000 in Natera, Inc. by purchasing 1,995 shares during the first quarter.
• Natera reported a loss per share of $0.74 for the latest quarter, missing analysts' expectations, despite revenue rising by 32.2% year-over-year to $546.6 million.
• Analysts have a consensus rating of "Buy" on Natera's stock, with price targets ranging from $195.00 to $255.00, indicating potential upside for investors.

Kaufman Rossin Wealth LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,995 shares of the medical research company's stock, valued at approximately $282,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Townsquare Capital LLC bought a new stake in Natera in the fourth quarter worth about $248,000. Mariner LLC raised its position in Natera by 7.0% in the fourth quarter. Mariner LLC now owns 9,769 shares of the medical research company's stock worth $1,546,000 after acquiring an additional 636 shares in the last quarter. NewEdge Advisors LLC raised its position in Natera by 107.0% in the fourth quarter. NewEdge Advisors LLC now owns 2,705 shares of the medical research company's stock worth $428,000 after acquiring an additional 1,398 shares in the last quarter. Commerce Bank raised its position in Natera by 17.7% in the fourth quarter. Commerce Bank now owns 2,650 shares of the medical research company's stock worth $419,000 after acquiring an additional 399 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Natera by 912.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,329 shares of the medical research company's stock worth $1,477,000 after acquiring an additional 8,408 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NTRA shares. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada lifted their price target on Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Barclays reissued an "overweight" rating and issued a $210.00 price target (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Piper Sandler reissued an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $193.19.

Natera Trading Up 2.3%

NASDAQ:NTRA traded up $3.65 on Friday, hitting $165.60. 839,847 shares of the company's stock traded hands, compared to its average volume of 1,655,524. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The firm has a 50-day moving average price of $154.85 and a 200-day moving average price of $154.16. The company has a market cap of $22.73 billion, a PE ratio of -86.70 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same period last year, the firm earned ($0.30) EPS. The company's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 6,111 shares of Natera stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.10, for a total transaction of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares of the company's stock, valued at $28,132,054.10. The trade was a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,792 shares of company stock worth $9,227,972. Insiders own 5.63% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.